Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy

The Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib has outstanding activity in patients with chronic lymphocytic leukemia. Most patients experience lymphocytosis, representing lymphocyte egress from nodal compartments. This resolves within 8 months in the majority of patients, but a subgroup has...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Woyach, Jennifer A., Smucker, Kelly, Smith, Lisa L., Lozanski, Arletta, Zhong, Yiming, Ruppert, Amy S., Lucas, David, Williams, Katie, Zhao, Weiqiang, Rassenti, Laura, Ghia, Emanuela, Kipps, Thomas J., Mantel, Rose, Jones, Jeffrey, Flynn, Joseph, Maddocks, Kami, O’Brien, Susan, Furman, Richard R., James, Danelle F., Clow, Fong, Lozanski, Gerard, Johnson, Amy J., Byrd, John C.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2014
Assuntos:
Clinical Trials and Observations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3962160/
https://ncbi.nlm.nih.gov/pubmed/24415539
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2013-09-527853
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados